Vir Biotechnology Announced Sunday, Expanded Phase 2 SOLSTICE Data For Elebsiran, Tobevibart In Chronic Hepatitis Delta, With 100% (28/28) Undetectable HDV RNA At Week 96, 100% (10/10) Sustained Viral Response After Treatment Discontinuation
Share
Why It Matters
Vir's medicine called Elebsiran showed very strong results. All patients had the virus drop to undetectable levels at week 96.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.